Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers Squibb : Myers Phase 3 Opdivo Study Misses a Main Endpoint

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/05/2019 | 07:52am EDT

By Colin Kellaher

Bristol-Myers Squibb Co. (BMY) on Thursday said a phase 3 study evaluating the addition of its cancer drug Opdivo to the current standard of care to treat a form of the aggressive tumor glioblastoma multiforme didn't meet the primary endpoint of progression-free survival.

The New York biopharmaceutical company, which remains blinded to the data, said the study's data monitoring committee recommended the trial continue as planned to allow the other primary endpoint, overall survival, to mature.

Bristol-Myers said the study involves the addition of Opdivo to the chemotherapy drug temozolomide and radiation therapy in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase-methylated.

Glioblastoma multiforme is the most common and most aggressive type of primary malignant tumor of the central nervous system.

Opdivo, which harnesses the body's immune system to fight cancer, has been approved for use in several types of cancer.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 1.00% 50.57 Delayed Quote.-3.67%
DNA OYJ 0.00% 20.88 Delayed Quote.22.25%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
07:00aBRISTOL MYERS SQUIBB : to Hold Investor Webcast to Discuss ESMO Highlights
BU
09/19BRISTOL MYERS SQUIBB : Research at ESMO Demonstrates Breadth of Oncology Develop..
BU
09/12BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers, Financial S..
AQ
09/12BRISTOL MYERS SQUIBB : Announces Dividend
AQ
09/12BRISTOL MYERS SQUIBB : to Announce Results for Third Quarter 2019 on October 31,..
BU
09/11BRISTOL MYERS SQUIBB : Board Announces Election of Three New Directors
PU
09/11BRISTOL MYERS SQUIBB : ‑Myers Squibb Announces Dividend
BU
09/10BRISTOL MYERS SQUIBB : Announces Pooled Five-Year Survival Results for Opdivo (n..
BU
09/06BRISTOL MYERS SQUIBB : Provides Update on Phase 3 Opdivo CheckMate -548 Trial in..
AQ
09/05BRISTOL MYERS SQUIBB : Myers Phase 3 Opdivo Study Misses a Main Endpoint
DJ
More news
Financials (USD)
Sales 2019 24 213 M
EBIT 2019 7 312 M
Net income 2019 6 676 M
Finance 2019 3 340 M
Yield 2019 3,29%
P/E ratio 2019 12,7x
P/E ratio 2020 8,34x
EV / Sales2019 3,28x
EV / Sales2020 2,76x
Capitalization 82 721 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 58,08  $
Last Close Price 50,57  $
Spread / Highest target 48,3%
Spread / Average Target 14,8%
Spread / Lowest Target -3,42%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-3.67%81 903
JOHNSON & JOHNSON1.05%343 382
ROCHE HOLDING LTD.16.27%243 639
MERCK AND COMPANY9.89%214 995
PFIZER-16.36%201 939
NOVARTIS15.60%198 194